Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions

ABSTRACT Furmonertinib demonstrated potent efficacy as a newly developed tyrosine kinase inhibitor for the treatment of patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer. In vitro research showed that furmonertinib is metabolized to its active metabol...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yali Wu, Helena Leonie Hanae Loer, Yifan Zhang, Dafang Zhong, Yong Jiang, Jie Hu, Uwe Fuhr, Thorsten Lehr, Xingxing Diao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2025-07-01
Edice:	CPT: Pharmacometrics & Systems Pharmacology
On-line přístup:	https://doi.org/10.1002/psp4.70052
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!